Osterlund, E., Maddalena, G., Vetere, G., Aziz, K., Kell, R. J., White, L., Gil, D. N., Yousef, M. M., Alfaro, K., Parseghian, C., Agrawal, N., Konishi, T., Raghav, K. P. S., Newhook, T. E., Shen, X., Shen, J. P. Y., Overman, M. J., Morris, V. K., Dasari, A., Kopetz, S. (2026). Stage-specific circulating tumor DNA (ctDNA) positivity and minimal residual disease (MRD) decision making in colorectal cancer (CRC) in the prospective INTERCEPT program.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3623